164 related articles for article (PubMed ID: 6136096)
1. [Drug abuse experience and neuroleptic prescriptions at the onset of schizophrenia].
Lisoprawski A
Sem Hop; 1983 Jun; 59(25):1925-7. PubMed ID: 6136096
[TBL] [Abstract][Full Text] [Related]
2. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
Potvin S; Stip E; Roy JY
Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
[TBL] [Abstract][Full Text] [Related]
3. [Dependence on anticholinergics among schizophrenics. Iatrogenic disease or self-medication?].
Chamorro García L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1991; 19(6):298-303. PubMed ID: 1687233
[TBL] [Abstract][Full Text] [Related]
4. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.
Cleghorn JM; Kaplan RD; Szechtman B; Szechtman H; Brown GM; Franco S
J Clin Psychiatry; 1991 Jan; 52(1):26-30. PubMed ID: 1671032
[TBL] [Abstract][Full Text] [Related]
5. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
6. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.
Potvin S; Stip E; Lipp O; Roy MA; Demers MF; Bouchard RH; Gendron A
Am J Drug Alcohol Abuse; 2008; 34(1):75-82. PubMed ID: 18161645
[TBL] [Abstract][Full Text] [Related]
7. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia.
Hamera E; Schneider JK; Deviney S
J Nerv Ment Dis; 1995 Sep; 183(9):559-65. PubMed ID: 7561817
[TBL] [Abstract][Full Text] [Related]
8. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls.
Schaub M; Fanghaenel K; Stohler R
Aust N Z J Psychiatry; 2008 Dec; 42(12):1060-5. PubMed ID: 19016094
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
10. Substance abuse in clozapine-treated schizophrenic patients.
Sand PG; Soyka M
J Neuropsychiatry Clin Neurosci; 1997; 9(4):626-7. PubMed ID: 9447510
[No Abstract] [Full Text] [Related]
11. [Effects and side effects of depot neuroleptics as perceived by patients].
Trenckmann U
Psychiatr Prax; 1990 Sep; 17(5):184-7. PubMed ID: 1980015
[TBL] [Abstract][Full Text] [Related]
12. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
Naber D
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
[TBL] [Abstract][Full Text] [Related]
13. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
Taira M; Hashimoto T; Takamatsu T; Maeda K
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
[TBL] [Abstract][Full Text] [Related]
14. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.
Jockers-Scherübl MC; Rentzsch J; Danker-Hopfe H; Radzei N; Schürer F; Bahri S; Hellweg R
Neurosci Lett; 2006 Jun; 400(3):262-6. PubMed ID: 16540246
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
Potvin S; Stip E; Lipp O; Elie R; Mancini-Marië A; Demers MF; Roy MA; Bouchard RH; Gendron A
Curr Med Res Opin; 2006 Jul; 22(7):1277-85. PubMed ID: 16834826
[TBL] [Abstract][Full Text] [Related]
16. [Incidence of the deficit form in refractory schizophrenia].
Samuelian JC
Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
[TBL] [Abstract][Full Text] [Related]
17. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
18. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
Pecknold JC
J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
[TBL] [Abstract][Full Text] [Related]
19. Self-reported prescribing practices for schizophrenic patients among Israeli psychiatrists.
Heresco-Levy U; Brom D; Greenberg D
Isr J Psychiatry Relat Sci; 1993; 30(3):164-74. PubMed ID: 7901179
[TBL] [Abstract][Full Text] [Related]
20. [Profile of the action of neuroleptics in deficit schizophrenia].
Vanelle JM
Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
